BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29957464)

  • 1. The unique DEK oncoprotein in women's health: A potential novel biomarker.
    de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
    Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing DEK downregulates cervical cancer tumorigenesis and metastasis via the DEK/p-Ser9-GSK-3β/p-Tyr216-GSK-3β/β-catenin axis.
    Xu X; Zou L; Yao Q; Zhang Y; Gan L; Tang L
    Oncol Rep; 2017 Aug; 38(2):1035-1042. PubMed ID: 28627610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
    Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
    Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DEK oncogene is overexpressed during melanoma progression.
    Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
    Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
    Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
    FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Complexity of DEK Signaling in Cancer Progression.
    Teng Y; Lang L; Jauregui CE
    Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
    Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
    PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nuclear DEK interactome supports multi-functionality.
    Smith EA; Krumpelbeck EF; Jegga AG; Prell M; Matrka MM; Kappes F; Greis KD; Ali AM; Meetei AR; Wells SI
    Proteins; 2018 Jan; 86(1):88-97. PubMed ID: 29082557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
    Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
    Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging-based study demonstrates how the DEK nanoscale distribution differentially correlates with epigenetic marks in a breast cancer model.
    Pierzynska-Mach A; Cainero I; Oneto M; Ferrando-May E; Lanzanò L; Diaspro A
    Sci Rep; 2023 Aug; 13(1):12749. PubMed ID: 37550322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the DEK oncogene in the development of squamous cell carcinoma.
    Ishida K; Nakashima T; Shibata T; Hara A; Tomita H
    Int J Clin Oncol; 2020 Sep; 25(9):1563-1569. PubMed ID: 32656741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.
    Privette Vinnedge LM; Ho SM; Wikenheiser-Brokamp KA; Wells SI
    PLoS One; 2012; 7(10):e46985. PubMed ID: 23071688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression of DEK is associated with poor prognosis in hepatocellular carcinoma.
    Lee SY; Jung W; Lee J; Kim A; Kim HK; Kim BH
    Histol Histopathol; 2019 Nov; 34(11):1279-1288. PubMed ID: 31066459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length.
    Fahrer J; Popp O; Malanga M; Beneke S; Markovitz DM; Ferrando-May E; Bürkle A; Kappes F
    Biochemistry; 2010 Aug; 49(33):7119-30. PubMed ID: 20669926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers.
    Privette Vinnedge LM; Benight NM; Wagh PK; Pease NA; Nashu MA; Serrano-Lopez J; Adams AK; Cancelas JA; Waltz SE; Wells SI
    Oncogene; 2015 Apr; 34(18):2325-36. PubMed ID: 24954505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of DEK in carcinogenesis, diagnosis, prognosis, and therapeutic outcome of breast cancer: An evidence-based clinical review.
    Habiburrahman M; Sutopo S; Wardoyo MP
    Crit Rev Oncol Hematol; 2023 Jan; 181():103897. PubMed ID: 36535490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of DEK and its regulation in tumorigenesis and metastasis of hepatocellular carcinoma.
    Yu L; Huang X; Zhang W; Zhao H; Wu G; Lv F; Shi L; Teng Y
    Oncotarget; 2016 May; 7(18):26844-55. PubMed ID: 27057626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The human DEK oncogene stimulates β-catenin signaling, invasion and mammosphere formation in breast cancer.
    Privette Vinnedge LM; McClaine R; Wagh PK; Wikenheiser-Brokamp KA; Waltz SE; Wells SI
    Oncogene; 2011 Jun; 30(24):2741-52. PubMed ID: 21317931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
    Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
    Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer.
    Datta A; Adelson ME; Mogilevkin Y; Mordechai E; Sidi AA; Trama JP
    BMC Cancer; 2011 Jun; 11():234. PubMed ID: 21663673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.